• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Intersect ENT, Inc.

    8/17/21 3:21:38 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care
    Get the next $XENT alert in real time by email
    SC 13G 1 versor-xent080921.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    INTERSECT ENT, INC.

    (Name of Issuer)

     

    Common stock, $0.001 par value per share

    (Title of Class of Securities)

     

    46071F103

    (CUSIP Number)

     

     

    August 9, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  46071F103
     SCHEDULE 13G
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Versor Investments LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    New York
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    1,736,079
    6
    SHARED VOTING POWER
     
    7
    SOLE DISPOSITIVE POWER
     
    1,736,079
    8
    SHARED DISPOSITIVE POWER
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,736,079
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.21%
    12
    TYPE OF REPORTING PERSON
     
    IV

     


     

    CUSIP No.  46071F103
     SCHEDULE 13G
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Asset Management Exchange Master ICAV
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Ireland
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    1,736,079
    6
    SHARED VOTING POWER
     
    7
    SOLE DISPOSITIVE POWER
     
    1,736,079
    8
    SHARED DISPOSITIVE POWER
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,736,079
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.21%
    12
    TYPE OF REPORTING PERSON
     
    OO

     


     

     

    CUSIP No. 46071F103
     SCHEDULE 13G
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    INTERSECT ENT, INC.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    1555 Adams Drive

    Menlo Park, California 94025

    Item 2.(a) Name of Person Filing

    Versor Investments LP

    Asset Management Exchange Master ICAV

    (b) Address of Principal Business Office, or, if none, Residence

    Versor Investments LP

    1120 Avenue of the Americas, 15th Floor

    New York, NY 10036

    Asset Management Exchange Master ICAV

    Riverside One, 37 - 42 Sir John Rogerson’s Quay

    Grand Canal Dock

    Dublin 2, D02 X576 Ireland

    (c) Citizenship

    Versor Investments LP

    New York

    Asset Management Exchange Master ICAV

    Ireland

    Item 2.(d) Title of Class of Securities

    Common stock, $0.001 par value per share (the “Common Stock”)

     

    Item 2.(e) CUSIP No.:

    46071F103

     

    CUSIP No.  46071F103
     SCHEDULE 13G
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 46071F103
     SCHEDULE 13G
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Information with respect to the Reporting Persons' ownership of the Common Stock as of August 9, 2021, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 46071F103
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 17, 2021

     

     

     

     

    Versor Investments LP

           
      By:  /s/ Andrew Flynn
        Andrew Flynn, Chief Operating Officer
           
     

    Asset Management Exchange Master ICAV

           
      By:  /s/ Andre Bruwer
        Andre Bruwer, Director
         

     
    CUSIP No. 46071F103
     SCHEDULE 13G
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: August 17, 2021

     

     

    Versor Investments LP

           
      By:  /s/ Andrew Flynn
        Andrew Flynn, Chief Operating Officer
           
     

    Asset Management Exchange Master ICAV

           
      By:  /s/ Andre Bruwer
        Andre Bruwer, Director
    Get the next $XENT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XENT

    DatePrice TargetRatingAnalyst
    8/12/2021$28.25Outperform → Market Perform
    SVB Leerink
    8/10/2021Buy → Neutral
    BTIG
    8/9/2021$29.00 → $28.25Buy → Hold
    Canaccord Genuity
    8/9/2021$28.25Buy → Neutral
    Guggenheim
    6/24/2021$21.00 → $23.00Market Perform → Outperform
    SVB Leerink
    More analyst ratings

    $XENT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intersect ENT downgraded by SVB Leerink with a new price target

    SVB Leerink downgraded Intersect ENT from Outperform to Market Perform and set a new price target of $28.25

    8/12/21 4:49:01 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT downgraded by BTIG

    BTIG downgraded Intersect ENT from Buy to Neutral

    8/10/21 5:09:28 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Intersect ENT from Buy to Hold and set a new price target of $28.25 from $29.00 previously

    8/9/21 10:22:16 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer

    Current President and CEO, Earl Fender, announces retirement CARLSBAD, Calif., July 14, 2022 /PRNewswire-PRWeb/ -- Nalu Medical, Inc. ("Nalu"), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas "Tom" West as President and Chief Executive Officer. This leadership appointment is effective on August 8th and follows the decision by Earl Fender, Nalu's current CEO, to retire. Mr. Fender will remain as a consultant to the company for the next 12 months. Mr. West remarked, "I am very excited and honored to be leading Nalu. I believe Nalu's unique system and technology, including the

    7/14/22 12:05:00 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Real-World Evidence Study Demonstrates Intersect ENT's PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

    Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, including all-cause otolaryngologist, ER/urgent care and outpatient visits, as well as sinus-related endoscopies Intersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced positive results of an observational, cohort study using real-world evidence (RWE) data from adult patients with chronic rhinosinusitis (CRS) with or without nasal polyps

    1/25/22 7:00:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Orthofix Announces Appointment of Thomas A. West to Board of Directors

    Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that Thomas A. West has been named to the Company's Board of Directors and appointed to the Compensation and Talent Development Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005343/en/Thomas A. West named to Orthofix Board of Directors and appointed to the Compensation and Talent Development Committee. (Photo: Business Wire) Mr. West currently serves as the President, Chief Executive Officer and Director of Intersect ENT, Inc. (NASDAQ:XENT), a commercial stage drug-device company that pioneers

    12/14/21 7:00:00 AM ET
    $OFIX
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    SEC Filings

    View All

    SEC Form POSASR filed by Intersect ENT Inc.

    POSASR - Intersect ENT, Inc. (0001271214) (Filer)

    9/12/22 5:25:28 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form RW WD filed by Intersect ENT Inc.

    RW WD - Intersect ENT, Inc. (0001271214) (Filer)

    9/12/22 1:10:59 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form 15-12B filed by Intersect ENT Inc.

    15-12B - Intersect ENT, Inc. (0001271214) (Filer)

    5/23/22 6:08:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SINUVA issued to INTERSECT ENT INC

    Submission status for INTERSECT ENT INC's drug SINUVA (SUPPL-6) with active ingredient MOMETASONE FUROATE has changed to 'Approval' on 01/20/2023. Application Category: NDA, Application Number: 209310, Application Classification: Labeling

    1/23/23 11:02:41 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Hattangadi Neil A

    4 - Intersect ENT, Inc. (0001271214) (Issuer)

    5/16/22 6:58:08 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Meier Richard A closing all direct ownership in the company

    4 - Intersect ENT, Inc. (0001271214) (Issuer)

    5/16/22 6:43:33 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Fernandez Reyna M closing all direct ownership in the company

    4 - Intersect ENT, Inc. (0001271214) (Issuer)

    5/16/22 6:41:18 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Intersect ENT Inc. (Amendment)

    SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)

    2/23/22 8:56:48 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Intersect ENT Inc. (Amendment)

    SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)

    2/17/22 11:40:20 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Intersect ENT Inc. (Amendment)

    SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)

    2/14/22 4:41:22 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Leadership Updates

    Live Leadership Updates

    View All

    Orthofix Announces Appointment of Thomas A. West to Board of Directors

    Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that Thomas A. West has been named to the Company's Board of Directors and appointed to the Compensation and Talent Development Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005343/en/Thomas A. West named to Orthofix Board of Directors and appointed to the Compensation and Talent Development Committee. (Photo: Business Wire) Mr. West currently serves as the President, Chief Executive Officer and Director of Intersect ENT, Inc. (NASDAQ:XENT), a commercial stage drug-device company that pioneers

    12/14/21 7:00:00 AM ET
    $OFIX
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT Announces Appointment of New Vice President of Sales

    Mark L. Alley to serve as Vice President of Sales Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced the appointment of Mark L. Alley as Vice President of Sales, effective May 10, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504005421/en/Mark L. Alley (Photo: Business Wire) Mr. Alley previously served as Chief Commercial Officer at medical device specialist Levita Magnetics Corp. He is a proven leader with over 20 years of commercial and sales success in companies ranging in size from start-ups to Fortune 500 compan

    5/4/21 7:00:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Financials

    Live finance-specific insights

    View All

    Intersect ENT Reports Third Quarter 2021 Financial Results

    Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter ended September 30, 2021. Total revenue was $24.4 million for the third quarter of 2021, up 7%, compared to $22.7 million for the same period of 2020. Gross profit for the third quarter of 2021 was $19.3 million and gross margin was 79.2%, compared to gross profit of $14.9 million and gross margin of 65.5% for the same period of 2020. Excluding the impact of intangible asset amortization, adjusted gross profit and adjusted gross margin for the third quarter of 2021 was $19.8 million and 81.2%, resp

    11/2/21 4:15:00 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT Reports Second Quarter 2021 Financial Results

    Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Overview Entered into a definitive agreement with Medtronic, in which Medtronic will acquire all outstanding shares of Intersect ENT. Revenue of $27.3 million in the second quarter of 2021, up 180%, compared to $9.8 million in the second quarter of 2020. Record quarterly SINUVA revenue of $2.7 million. Global Navigation and Balloon portfolio generated quarterly revenue of $1.6 million. Cash, cash equivalents, restricted cash, and short-term investm

    8/6/21 7:15:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT to Report Second Quarter 2021 Financial Results on August 6

    Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced that it will release second quarter 2021 financial results on Friday, August 6, 2021. The Company expects to issue the release at approximately 7:00 a.m. ET and management will host a conference call at 8:30 a.m. ET. To access the conference call via the Internet, go to the "Investor Relations" page of the Company's website at www.intersectENT.com. To access the live conference call via phone, dial 844-850-0548 and ask to join the Intersect ENT call. International callers may access the live call by dialing 412-317-5205. Participants may

    7/23/21 8:00:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care